research report · PFE

Pfizer Inc

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 3, 2026 from its quarterly report (10-Q for the quarter ended Sep 27, 2026, filed Nov 3, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Stable

little material change

financial resilience

Adequate

funded for about two years, partly by routine borrowing or new issuance

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Pfizer's core business is growing, but more narrowly than the headline suggests, and the heaviest price and patent pressure arrives in 2027–2028. Revenue excluding COVID products grew 7% operationally in the third quarter. By my calculation, about half of that dollar growth was Eliquis, whose U.S. gain the company attributes primarily to higher net price. Cash covers the dividend with modest room: roughly $11.8B of trailing-twelve-month free cash flow against about $9.8B of dividends (my calculation). Meanwhile $62.7B of debt is expected to stay around current levels or rise modestly.

what changed this quarter

  • Revenue was $16.6B, flat on a year earlier. Paxlovid fell 63% and Comirnaty 29% operationally; everything else grew 7%.
  • Diluted EPS was $0.56 versus $0.62. Adjusted EPS was $0.87 in both years, after a $650M Innovent upfront charge worth about $0.10.
  • 2026 guidance was raised: revenue to $62.0–64.0B from $60.5–62.5B, adjusted EPS to $2.95–3.05 from $2.80–3.00, and adjusted R&D to $10.8–11.8B.
  • Two new cost phases target about $2.5B of extra net savings in 2027–2029, for about $6.0B of one-time costs.
  • Cecile Guegan, interim CFO since August 16, became CFO from November 1. A failed Phase 3 trial drove a $3.8B write-down of sigvotatug vedotin.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • About half of non-COVID growth was Eliquis pricing, a gain with a deadline
  • The 2027–2028 exposure is larger than the growth engines
  • Savings are being recycled into spending, not banked
  • Acquired pipeline value is written off faster than it reaches market

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what PFE files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on PFE say?” Add Viridis to Claude, or to ChatGPT.